Literature DB >> 11317480

Initial uptake in use of sildenafil in general practice.

D Williams1, J Feely.   

Abstract

OBJECTIVE: To assess the initial uptake in use and co-prescribing patterns of sildenafil.
METHODS: We examined prescription details of the Eastern Health Board Region (including Dublin) of the General Medical Services (GMS) in Ireland, which provides detail on prescriptions dispensed in primary care for this population (n = 334,031). We identified 1422 patients who received 3740 prescriptions for sildenafil over a 6-month period (July 1999-December 1999) and determined the percentage of patients who were co-prescribed nitrate therapy, medications which may interact with sildenafil and medications associated with impotence.
RESULTS: We identified 1422 (1.4% of the male population over 16 years who might be expected to suffer from erectile dysfunction given an overall prevalence of 10%) who received a prescription for sildenafil over the study period at a cost of 0.14% of the annual drug budget. Up to 2.5%, 6% and 25% of patients were co-prescribed, respectively, nitrate therapy, potentially interacting drugs and drugs associated with impotence.
CONCLUSION: The initial uptake and cost associated with sildenafil was lower than expected. The rate of prescribing of nitrates and other potentially interacting medications was found to be low. Medication use may also contribute to erectile dysfunction in this population of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11317480     DOI: 10.1007/s002280000255

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  1 in total

1.  The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions.

Authors:  Edward C F Wilson; Emma S McKeen; Paul A Scuffham; Martin C J Brown; Kevan Wylie; Geoff Hackett
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.